A recent boom in psychedelic research has given way to a bumper crop of startups seeking to harness the potential of mind-altering drugs for treating depression, addiction and other conditions. MindMed has a unique approach: extracting drugs like psilocybin and mescaline from natural sources , including mushrooms and cacti, rather than synthesizing the ingredients in a laboratory. MindMed is studying its mushroom-based psilocybin as a treatment for opioid and stimulant use disorder .
And more than a dozen other companies and academic centers are using the company’s drugs in trials of depression, chronic pain and other disorders. CEO Benjamin Lightburn spoke with The Associated Press about the ethical, therapeutic and medical case for using naturally derived psychedelics. The answers have been edited for length and clarity. A: It means we’re deriving them from natural sources, like plants and fungi, because that is in fact the way that humanity has been interacting with these substances in their natural form for thousands of year
Source: News Formal (newsformal.com)
Psychedelic Research Startups Mind-Altering Drugs Depression Addiction Natural Sources Psilocybin Mescaline Mushrooms Cacti Laboratory Treatment Opioid Use Disorder Stimulant Use Disorder Trials Chronic Pain Disorders Benjamin Lightburn Ethics Therapy Medicine
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: wjxt4 - 🏆 246. / 63 Read more »
Source: NYMag - 🏆 111. / 63 Read more »
Source: FoxNews - 🏆 9. / 87 Read more »
Goodwill CEO opens new stores, but it’s all about the workforceAs Goodwill CEO, Carlos Contreras has opened new stores, but it’s all about the workforce.
Source: ExpressNews - 🏆 519. / 51 Read more »
Source: latimes - 🏆 11. / 82 Read more »
Source: FoxBusiness - 🏆 458. / 53 Read more »